A genetic abnormality may be a critical factor for the development of late onset Alzheimer’s disease, an international team of researchers has discovered. Impairments to the gene, known as SORL1 could lead to the formation of amyloid plaques, the feature sign of Alzheimer’s in the brains of people with the disease.
The genetic clue, which could lead to a better understanding of one cause of Alzheimer’s, is reported in the journal Nature Genetics.
Researchers identified 29 variants of the gene that mark relatively short segments of DNA where disease-causing changes could lie. The study did not, however, identify specific genetic changes that result in Alzheimer’s.
The study involved 14 collaborating institutions in North America, Europe and Asia, and 6,000 individuals who donated blood for genetic typing.
“We do not fully understand what causes Alzheimer’s disease, but we know that genetic factors can play a role,” says National Institute on Aging director Richard J. Hodes, M.D.
“Scientists have previously identified three genes, variants of which can cause early onset Alzheimer’s, and one that increases risk for the late onset form. This discovery provides a completely new genetic clue about the late onset forms of this very complex disease. We are eager to investigate the role of this gene further.”
Scientists think that in Alzheimer’s disease, amyloid precursor protein, or APP, is processed into amyloid beta protein fragments that make up plaques in the brain. The researchers began their search for genetic influences amid a group of proteins that transport APP within cells, looking for small changes, or “misspellings,” in seven genes involved in moving APP within cells.
To start, the scientists combed two large data sets of genetic information from families in which more than one person has Alzheimer’s disease. They were soon able to see that many of the families with Alzheimer’s had variations in the SORL1 gene but not consistently in any of the other six genes.
They then expanded their search to genetic data sets from families of Northern European, Caribbean Hispanic, Caucasian, African American, and Israeli Arab heritage for changes in the SORL1 gene. Again, they found the same association between SORL1 variations and Alzheimer’s disease.
Searching additional data sets provided by Steven Younkin, M.D., Ph.D., of the Mayo Clinic further confirmed the association of SORL1 variations and Alzheimer’s.
Examining blood cells from people with and without Alzheimer’s, the researchers found less than half the level of SORL1 protein in people with Alzheimer’s compared to people without the disease.
In laboratory experiments, they found that altering the levels of SORL1 changed the way APP was moved around in cells, with low levels of SORL1 resulting in increased production of amyloid beta fragments while high levels decreased production.
However, the researchers note, other genetic and non-genetic factors are likely to affect SORL1 production in people, and more research is needed to determine the how different versions of the SORL1 gene influence production of the harmful protein fragments.